The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population
Open accessAbstract
PURPOSE: Patients with locally advanced prostate cancer after radical prostatectomy are candidates for secondary therapy. However, this higher risk population is heterogeneous. Many cases do not metastasize even when conservatively managed. Given the limited specificity of pathological features to predict metastasis, newer risk prediction models are needed. We report a validation study of a genomic classifier that predicts metastasis after radical prostatectomy in a high risk population. MATERIALS AND METHODS: A case-cohort design was used to sample 1,010 patients after radical prostatectomy at high risk for recurrence who were treated from 2000 to 2006. Patients had preoperative prostate specific antigen greater than 20 ng/ml, Gleason 8 or greater, pT3b or a Mayo Clinic nomogram score of 10 or greater. Patients with metastasis at diagnosis or any prior treatment for prostate cancer were excluded from analysis. A 20% random sampling created a subcohort that included all patients with metastasis. We generated 22-marker genomic classifier scores for 219 patients with available genomic data. ROC and decision curves, competing risk and weighted regression models were used to assess genomic classifier performance. RESULTS: The genomic classifier AUC was 0.79 for predicting 5-year metastasis after radical prostatectomy. Decision curves showed that the genomic classifier net benefit exceeded that of clinical only models. The genomic classifier was the predominant predictor of metastasis on multivariable analysis. The cumulative incidence of metastasis 5 years after radical prostatectomy was 2.4%, 6.0% and 22.5% in patients with low (60%), intermediate (21%) and high (19%) genomic classifier scores, respectively (p<0.001). CONCLUSIONS: Results indicate that genomic information from the primary tumor can identify patients with adverse pathological features who are most at risk for metastasis and potentially lethal prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1914 · Cited by 1,029
Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
ROEHL, K. A., HAN, M., RAMOS, C. G., ANTENOR, J. A. V., & CATALONA, W. J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000134888.22332.bb · Cited by 861
Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, R., Störkel, S., Willich, N., Semjonow, A., Souchon, R., Stöckle, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9563 · Cited by 825
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., DiBlasio, C. J., Reuther, A., Klein, E. A., & Kattan, M. W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.867 · Cited by 663
Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
Self-citationCooperberg, M. R., Hilton, J. F., & Carroll, P. R. (2011) · Cancer · doi:10.1002/cncr.26169 · Cited by 457
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2501 · Cited by 419
Prostate cancer epidemiology in the United States
Brawley, O. W. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0824-2 · Cited by 333
Cox Regression with Incomplete Covariate Measurements
Lin, D. Y., & Ying, Z. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476416 · Cited by 255
Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans
Uchio, E. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.262 · Cited by 82
Discovery of prostate cancer biomarkers by microarray gene expression profiling
Sørensen, K. D., & Orntoft, T. F. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.74 · Cited by 65
Prognostic Factors for Failure after Prostatectomy
Swanson, G. P., & Basler, J. W. (2011) · Journal of Cancer · doi:10.7150/jca.2.1 · Cited by 57
Shipley, W. U., Hunt, D. L., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Patel, M., Bahary, J.-P., Lawton, C. A., & Sandler, H. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.103 · Cited by 47
Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
Vergara, I. A., Erho, N., Triche, T. J., Ghadessi, M., Crisan, A., Sierocinski, T., Black, P. C., Buerki, C., & Davicioni, E. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00023 · Cited by 24
Self-citationAlshalalfa, M., Crisan, A., Vergara, I. A., Ghadessi, M., Buerki, C., Erho, N., Yousefi, K., Sierocinski, T., Haddad, Z., Black, P. C., et al. (2014) · British Journal of Urology · doi:10.1111/bju.13013 · Cited by 21
Self-citationSchubert, M., Joniau, S., Gontero, P., Kneitz, S., Scholz, C. J., Kneitz, B., Briganti, A., Karnes, R. J., TOMBAL, B. F., Walz, J. C., et al. (2012) · Advances in Urology · doi:10.1155/2012/612707 · Cited by 10
Self-citation
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Prensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2771 · Cited by 669
Self-citationThe oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
Chakravarty, D., Sboner, A., Nair, S. S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J. M., Pauwels, J., Park, K., Kossai, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6383 · Cited by 621
Self-citationA new era: artificial intelligence and machine learning in prostate cancer
Goldenberg, S. L., Nir, G., & Salcudean, S. E. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0193-3 · Cited by 511
Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 308
Self-citation
Metadata
- Authors
- Karnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., Carlson, R., Thompson, D. J. S., Haddad, Z., Zimmermann, B., Sierocinski, T., Triche, T. J., Kollmeyer, T., Ballman, K. V., Black, P. C., Klee, G. G., & Jenkins, R. B.
- Venue
- Journal of Urology
- Published
- 2013-12
- Volume
- 190
- Issue
- 6
- Pages
- 2047-2053
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1972298018
- Cited by
- 325
- References
- 25
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.